Cyclopropylamines as LSD1 inhibitors

Patent metadata

Field	Value
Publication number	US-10676457-B2
Application number	US-201815970954-A
Country	US
Kind code	B2
Filing date	May 4, 2018
Priority date	Feb 13, 2014
Publication date	Jun 9, 2020
Grant date	Jun 9, 2020

Abstract

The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

First claim

What is claimed is:

1. A method of treating a cancer selected from myelodysplasia syndrome, acute myelogenous leukemia, undifferentiated small cell lung cancer, Ewing's sarcoma, and primary myelofibrosis, comprising administering to a patient a therapeutically effective amount of 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the cancer is myelodysplasia syndrome.

3. The method of claim 1 , wherein the cancer is acute myelogenous leukemia.

4. The method of claim 1 , wherein the cancer is undifferentiated small cell lung cancer.

5. The method of claim 1 , wherein the cancer is Ewing's sarcoma.

6. The method of claim 1 , wherein the cancer is primary myelofibrosis.

Assignees

• Incyte Corp

Inventors

• Wu Liangxing
• Yao Wenqing

Classifications

• C07D211/26

  with hydrocarbon radicals, substituted by nitrogen atoms · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D405/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D211/58

  attached in position 4 · CPC title

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title